Cellectar Biosciences (CLRB)
(Delayed Data from NSDQ)
$3.02 USD
+0.50 (19.84%)
Updated Jul 22, 2024 04:00 PM ET
After-Market: $3.03 +0.01 (0.33%) 6:42 PM ET
3-Hold of 5 3
D Value C Growth F Momentum D VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
CLRB 3.02 +0.50(19.84%)
Will CLRB be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for CLRB based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for CLRB
Is Cellectar Biosciences (CLRB) Outperforming Other Medical Stocks This Year?
CLRB: What are Zacks experts saying now?
Zacks Private Portfolio Services
Other News for CLRB
Cellectar Biosciences Announces Exercise of Tranche B Warrants and Purchase of New Warrants for Approximately $19.4 million with the Potential to Raise Up to an Additional $73.3 Million
Cellectar Biosciences Bolsters Capital with Warrant Exercise Strategy
Cellectar Biosciences to Host Key Opinion Leader Event to Review the Full Results from Its CLOVER WaM Pivotal Trial and Waldenstrom’s Macroglobulinemia Market Landscape
Cellectar Biosciences Shareholders Back Leadership and Incentives
Cellectar Biosciences and City of Hope Cancer Center Enter Collaboration to Evaluate Iopofosine I 131 in Mycosis Fungoides